Get informed when a big investor buys or sells
+ FollowOvervalued by 35.9% based on the discounted cash flow analysis.
Loading insider trades…
Loading congress trades…
| Market cap | $3.41 Billion |
|---|---|
| Enterprise Value | $3.41 Billion |
| Annual dividend | $0.63 |
| Dividend yield | 1.57% |
| Earnings per Share | $1.52 |
| Beta | 1.46 |
| Outstanding Shares | 86,302,842 |
| P/E Ratio | 20.95 |
|---|---|
| PEG | 22.3 |
| Price to Sales | 1.3 |
| Price to Book Ratio | 1.62 |
| Enterprise Value to Revenue | 1.28 |
| Enterprise Value to EBIT | 14.16 |
| Enterprise Value to Net Income | 29 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
No data
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Holdings and activity of institutional investors.
| Ownership % | 0.00%0% |
|---|---|
| Total Invested | $113▼ 82.75% |
| Investors Holding | 10% |
Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for ...